CagriSema
Cagrilintide/Semaglutide
A fixed-dose combination of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, studied in phase 3 trials for weight management and for glycemic control in type 2 diabetes. Both components are given on a weekly schedule. Not approved.
Tracking and educational reference only, on values you enter yourself. Not medical advice or a dosing recommendation.
Regulatory status
Investigational
This substance is under study in humans, typically under a regulatory authorization such as an Investigational New Drug application. Investigational describes a stage of research and nothing more: it does not mean approval is coming, and it does not indicate that effectiveness has been established.
A regulatory status describes paperwork, not safety. An approved compound can still be wrong for a given person, and an unapproved one is neither thereby dangerous nor thereby fine.
Half-life
About one week for both components, consistent with the weekly schedule used in trials. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Investigational; no approved label defines handling.
References
- NEJM 2025: coadministered cagrilintide and semaglutide in adults with overweight or obesity
- NEJM 2025: cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes
Read the source
Common questions
CagriSema, answered plainly.
01What is CagriSema?+
A fixed-dose combination of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, studied in phase 3 trials for weight management and for glycemic control in type 2 diabetes. Both components are given on a weekly schedule. Not approved. It is also referred to as Cagrilintide/Semaglutide. It is listed here under GLP-1 / Metabolic as educational reference, which is not a recommendation to use it.
02Is CagriSema FDA approved?+
Investigational. This substance is under study in humans, typically under a regulatory authorization such as an Investigational New Drug application. Investigational describes a stage of research and nothing more: it does not mean approval is coming, and it does not indicate that effectiveness has been established.
03What is the half-life of CagriSema?+
About one week for both components, consistent with the weekly schedule used in trials. A half-life is an educational pharmacology figure describing how long the body takes to clear half of a substance. It is not a schedule and does not imply one.
04How is CagriSema stored and handled?+
Investigational; no approved label defines handling. Storage conditions come from a manufacturer's own label where one exists, and a compound with no approved label has no agency-reviewed handling instructions at all.
Compare CagriSema
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.